Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer

Acta Medica Okayama

Volumn 60, Issue 1, 2006, Pages 43-49

  Kaku, Haruki ^a   Saika, Takashi ^a   Tsushima, Tomoyasu ^b   Nagai, Atsushi ^a   Yokoyama, Teruhiko ^a   Abarzua, Fernando ^a   Ebara, Shin ^a   Manabe, Daisuke ^a   Nasu, Yasutomo ^a   Kumon, Hiromi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Chemotherapy; Cisplatin; Estramustine phosphate; Hormone refractory prostate cancer; Ifosfamide

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CISPLATIN; ESTRAMUSTINE; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ESTRAMUSTINE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33645840484     PISSN: 0386300X     EISSN: 0386300X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM and Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 14: 1756-1764.
2. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP and Vogelzang NJ: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 17: 2506-2513.
3. Berry W, Dakhil S, Modiano M, Gregurich M and Asmar L: Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol (2002) 168: 2439-2443.
4. Maki Y, Tsushima T, Nasu Y, Kumon H, Ohmori H, Tanahashi T, Nanba K, Ohashi T, Kondo K, Saika T, Asahi T, Saegusa M, Ozaki Y, Yamashita Y, Katayama Y, Kobuke M, Uno S, Ochi J, Kobashi K and Hata K: Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive cancer. Nippon Hinyokika Gakkai zasshi (Jpn J Urol) (1998) 89: 657-664 (in Japanese).
5. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M and Roth B: Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network Phase III trial. J Clin Oncol (1999) 17: 3160-3166.
6. The Japanese Urological Association and The Japanese Society of Pathology: General Rules for Surgical and Pathological Studies on Prostate Cancer (3 edition), Kanehara & Co., Ltd., Tokyo (2001) (in Japanese).
7. Tsushima T and Kumon H: Chemotherapy for endocrine therapy-refractory prostate cancer. Japanese Journal of Urological Surgery (2000) 13: 753-760 (in Japanese).
8. Seidman AD, Scher HI, Petrylak D, Dershaw DD and Curley T: Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol (1992) 147: 931-934.
9. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, Watts P, Speicher L, Tew K and Comis R: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractry prostate cancer. J Clin Oncol (1992) 10: 1754-1761.
10. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S and McAleer C: Phase II trail of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol (1997) 15: 3156-3163.
11. Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T and Hudes G: Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology (2001) 58: 59-64.
12. Smith DC, Esper P, Strawderman M, Redman B and Pienta KJ: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol (1999) 17: 1664-1671.
13. Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W and Scher H: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol (2001) 19: 44-53.
14. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B and Vinciguerra V: Phase I trial of the comnbination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol (1999) 10: 33-38.
15. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M and Olsson CA: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol (1999) 17: 958-967.
16. Savarese D, Taplin ME, Halabi S, Hars V, Kreis W and Vogelzang N: A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. Semin Oncol (1999) 26 (suppl. 17): 39-44.
17. Pienta KJ Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H and Smith DC: A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology (1997) 50: 406-407.
18. Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, Costantinidis C, Kostakopoulos A, Kastriotis I, Zervas A, Aramantinos G and Dimopoulos C: Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology (1997) 50: 754-758.
19. Culine S Kattan J, Zanetta S, Theodore C, Fizazi K and Droz JP: Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Am J Clin Oncol (1998) 21: 470-474.